[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wounds\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wounds":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,77,114,141,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100449578","examining-the-use-of-three-dimensional-ultrasound-in-the-assessment-of-vascular-pathologies-100449578",false,"NCT05134311","Examining the Use of Three Dimensional Ultrasound in the Assessment of Vascular Pathologies","3D-US","Inclusion Criteria:\n\n* Age 18 years of age or older\n* Suspected vascular insufficiency that requires ultrasound evaluation\n* Subject is able to sign a consent form\n* Scheduled ultrasound testing at the wound center to evaluate vasculature\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Subject is not scheduled to have ultrasound testing at the wound center\n* Subject is unable to or refuses to consent to participate","ALL","18 Years",{"count":19,"type":20},270,"ESTIMATED","INTERVENTIONAL",[23],"NA","The ability to have a visual aid to depict areas of vascular disease that are affecting the patient's health can help in patient comprehension of the problem. This comprehension can lead to better understanding of the issue and increase patient compliance to treatment. The hand drawn sketch produced by the ultrasound technologist provides an inadequate visualization of the vascular insufficiency that is causing the patient's symptoms.\n\nPIUR imaging has developed PIUR Infinity tUS, a 3D freehand tomographic ultrasound system capable of rapid, safe and accurate reconstructive 3D quantifiable vascular imaging. This system will provide a low cost and reproducible imaging solution that will be an effective educational tool for people with vascular disease.",[26,27,28],"PAD - Peripheral Arterial Disease","Vascular Diseases","Wounds","RECRUITING","2026-06-11",{"date":32,"type":33},"2026-06-15","ACTUAL",{"date":35,"type":33},"2025-07-01",{"date":37,"type":20},"2028-09-01",{"name":39,"class":40},"Northwell Health","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":61,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100586924","pilot-trial-for-woundx-clinical-decision-support-tool-100586924","NCT06921707","Pilot Trial for WounDx™ Clinical Decision Support Tool","SC2i-WounDx-001-WounDx™ Pilot Trial: Proof of Concept Feasibility for the Clinical Operations of WounDx™ in Aiding Clinicians Identify Wounds That Are Ready For Surgical Closure","Inclusion Criteria:\n\n* Wound surface area ≥75cm 2\n* Extremity injury (including shoulder and buttock - without visceral communication)\n* Wound amenable to Negative Pressure Wound Therapy using 3M™ V.A.C. ® canisters without gel pack\n\nExclusion Criteria:\n\n* Insulin Dependent Diabetes\n* Peripheral Vascular Disease\n* Connective Tissue Disorders\n* Preexisting immunosuppressive conditions or immunosuppression therapy\n* Pregnancy\n* Prisoners","65 Years",{"count":51,"type":20},40,[23],"The purpose of this research is to evaluate the overall use of the WounDx medical device in a clinical setting, such as a hospital. The WounDx device is experimental and not yet approved by the United States Food and Drug Administration (FDA). WounDx uses information about a patient's wound to generate a report that a surgeon may use to help determine when to close or not close the wound. The final decision to close the wound remains with the surgeon. The results from this pilot trial will inform a larger pivotal trial.",[28,55,56,57,58,59,60],"Wounds and Injuries","Extremity Injury","Traumatic Wounds and Injuries","Amputation, Traumatic\u002FSurgery","Amputation, Wound","Open Fracture Wounds",[28,56,62,63,64,65,66],"Clinical Decision Support Tool","Delayed Wound Closure","Cytokine Biomarkers","Wound Effluent","Traumatic Extremity Wounds","2026-04-14",{"date":69,"type":33},"2026-04-17",{"date":71,"type":20},"2026-03-21",{"date":73,"type":20},"2026-09-20",{"name":75,"class":40},"Henry M. Jackson Foundation for the Advancement of Military Medicine",5,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":89,"conditions":90,"keywords":98,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100570426","phase-3-tissue-repair-gel-in-venous-leg-ulcers-us-100570426","NCT06707090","Tissue Repair Gel in Venous Leg Ulcers (US)","A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)","TRIVIA","Inclusion Criteria:\n\n* Adults 18 years and older\n* Venous insufficiency has been clinically diagnosed clinically and medically confirmed.\n* Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control.\n* The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.\n* Target ulcer age must be ≥ 4 weeks at Screening.\n* Participants must have adequate arterial flow as confirmed by ABI\u002FTBI, TB, SPP, TCPo2, or Duplex Doppler.\n* Body mass index (BMI) ≤ 50 kg\u002Fm2.\n* HbA1C ≤12%.\n\nExclusion Criteria:\n\n* Target ulcer has been treated with prohibited medications or therapies.\n* History of radiation at the target ulcer site.\n* Target ulcer decreases in area by 30% or more during screening period.\n* History of osteomyelitis at the target ulcer within 6 months of screening.\n* Participants considered nutritionally deficient.",{"count":86,"type":20},312,[88],"PHASE3","The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.",[91,92,93,94,95,28,96,97],"Venous Leg Ulcer","Venous Ulcer","Venous Stasis Ulcer","Venous Stasis","Wound Heal","Venous Insufficiency of Leg","Non-healing Wound",[99,100,101,102,103],"Tissue Repair","Glucoprime","TR Therapeutics","Debridement","VLU","2026-02-09",{"date":106,"type":33},"2026-02-12",{"date":108,"type":33},"2025-01-28",{"date":110,"type":20},"2028-02",{"name":101,"class":112},"INDUSTRY",33,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":41},"100541692","phase-2-4-aminopyridine-for-skin-wound-healing-100541692","NCT06333171","4-aminopyridine for Skin Wound Healing","Inclusion Criteria:\n\n* Otherwise healthy adult patients without skin conditions effecting the skin of the axilla or upper inner arm.\n* Cognitive ability to evaluate wound healing, report sensory and motor deficit during examination.\n* Eligible for standard of care plan for wound closure by secondary intention (normal healing without intervention).\n* Adults subject aged 18-70\n* Ability to give written informed consent.\n* Capable of safely coming in for follow up visits on all scheduled appointments.\n\nExclusion Criteria:\n\n* History of multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of hypersensitivity to AMPYRA® or 4-aminopyridine\n* Current use of aminopyridine medications, including other compounded 4-AP\n* Suspected renal impairment based on the Choyke questionnaire.\n* History of difficult compliance with timely follow up\n* Patients outside the age range\n* Unable to provide informed consent.\n* Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity).\n* Patients with a concomitant traumatic brain injury.\n* Patients unable to communicate.\n* Patients unwilling to complete the study requirements.\n* Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine.\n* Pregnancy, breastfeeding or incarcerated individuals.\n* Non-English speaking\n* Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds",true,"70 Years",{"count":123,"type":20},150,[125],"PHASE2","Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults.\n\nThe purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing.\n\nThe investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing.",[28,128,95,55],"Wound of Skin",[130,131],"4 aminopyridine","wound healing","2025-09-01",{"date":134,"type":33},"2025-09-03",{"date":136,"type":20},"2025-09",{"date":138,"type":20},"2028-03",{"name":140,"class":40},"John Elfar",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":21,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100485995","a-clinical-investigation-to-follow-the-progress-of-exuding-chronic-venous-leg-ulcers-using-a-non-bordered-foam-dressing-100485995","NCT05608317","A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam Dressing","A Prospective, Open, Multi-Center, Interventional, Non-Comparative Clinical Investigation to Follow the Progress of Exuding Venous Leg Ulcers Using a Non-Bordered Foam Dressing","Inclusion Criteria:\n\n* Signed consent to participate (including consent for digital imaging)\n* Adult aged ≥18 years\n* Diagnosed with a chronic, exuding VLU\n* Exudate amount moderate to large\n* Wound size from 3 cm2 to 30 cm2, as determined by the clinician\n* ABPI (within 3 months) \\> 0.7. If ABPI \\> 1.4, then big toe pressure \\> 60 mmHg is required or an alternative measurement verifying normal distal arterial flow\n* Willing to be compliant with compression therapy\n\nExclusion Criteria:\n\n* Infected ulcer according to the judgment of the investigator defined as any wound condition requiring the prescription or continuation of systemic antibiotic therapy at enrollment\n* Circumferential wound\n* Known allergy\u002Fhypersensitivity to the materials of the dressing\n* Use of wound fillers",{"count":149,"type":20},20,[23],"The goal of this clinical trial to follow the progress of wounds in those with chronic venous leg ulcers while using a non-bordered foam dressing. The main objective is to follow the progress of these wounds over time from initial visit to each follow-up visit.\n\nParticipants will be asked to wear the dressing for up to 6 weeks of treatment or until healed, changed at every one-week interval.",[28,128,153,91],"Wound Leg",[91],"2024-05-03",{"date":157,"type":33},"2024-05-06",{"date":159,"type":33},"2022-11-08",{"date":161,"type":20},"2024-11-30",{"name":163,"class":112},"Molnlycke Health Care AB",3,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":174,"briefSummary":175,"conditions":176,"keywords":179,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},"100484479","a-clinical-investigation-to-follow-the-progress-of-exuding-chronic-wounds-using-mepilex-up-as-the-primary-dressing-100484479","NCT05588583","A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.","A Prospective, Open, Multi-Center, Interventional, Non-Comparative Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up","Inclusion Criteria:\n\n* Signed consent to participate (including consent for digital imaging)\n* Adult aged ≥18 years\n* Diagnosed with a chronic, exuding VLU or DFU\n* Exudate amount moderate to large\n* Wound size from 3 cm2 to 30 cm2 for VLU and ≥1 cm2 for DFU, as determined by the clinician\n* For VLU: ABPI (within 3 months) \\> 0.7. If ABPI \\> 1.4, then big toe pressure \\> 60 mmHg is required or an alternative measurement verifying normal distal arterial flow\n* For VLU: Willing to be compliant with compression therapy\n\nExclusion Criteria:\n\n* Infected ulcer according to the judgment of the investigator defined as any wound condition requiring the prescription or continuation of systemic antibiotic therapy at enrollment\n* Circumferential wound\n* Known allergy\u002Fhypersensitivity to the materials of the dressing\n* Patients participating in the DIPLO NBF study\n* Use of wound fillers",{"count":173,"type":20},68,[23],"The goal of this clinical trial is to follow the progress of wounds in those with venous leg ulcers and diabetic foot ulcers while using an absorbent dressing called Mepilex Up. The main objective is to follow the progress of these wounds over time from initial visit to each follow-up visit.\n\nParticipants will be asked to wear Mepilex Up dressing for up to 6 weeks of treatment or until healed, changed at every one-week interval.",[28,128,153,177,178,91],"Wound; Foot","Diabetic Foot Ulcer",[178,91],"2023-04-18",{"date":182,"type":33},"2023-04-20",{"date":184,"type":33},"2022-10-31",{"date":186,"type":20},"2024-03",{"name":163,"class":112},4]